Effect of serum glucose-6-phosphate isomerase in disease activity and bone erosion of rheumatoid arthritis
CHEN Yalin1, ZHANG Liqing2, ZHANG Jinrong3
1. Shanxi Medical University, Taiyuan 030001, China; 2. Department of Rheumatology,3. Department of Radiology, Fenyang Hospital of Shanxi Province, Fenyang 032200, China
Objective To investigate the relationship between serum glucose-6-phosphate isomerase (GPI) and disease activity in patients with rheumatoid arthritis (RA) and its role in bone erosion. Methods One hundred and five patients with RA, who were admitted to the Department of Rheumatology, Fenyang Hospital of Shanxi Province from August 2019 to February 2021, were divided into GPI positive group and GPI negative group according to the titer of serum GPI determined by enzyme-linked immunosorbent assay (ELISA). The two groups were compared in the clinical data and laboratory indexes which included swollen joint count(SJC), tender joint count(TJC), anti-cyclic citrullinated peptide (CCP) antibody, rheumatoid factor (RF), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), the 28-joint disease activity score (DAS28)was calculated , conventional radiographs of bilateral hands and bone mineral density was performed, and the Sharp score was also calculated. All patients were given standard treatment and followed up regularly, disease activity was assessed after 3, 6, 9 and 12 months' treatment, DAS28 scores were recorded, and radiological indexes were reviewed after one year's treatment. Results SJC[5.00(4.00, 6.00)],TJC[6.00(5.00, 8.75)],ESR[(58.70±23.40) mm/h)],CRP[21.82(13.55, 31.90) mg/L] and DAS28 score(5.44±0.69) in GPI positive group were higher than GPI negative group[4.00(3.00, 5.00)、5.00(5.00, 7.00)、(48.72±19.87) mm/h、14.37(6.49, 26.56) mg/L、(5.05±0.50)], there were statistically differences(P<0.05). Serum GPI level was positively correlated with SJC(r=0.317, P=0.046),TJC(r=0.389, P=0.013),ESR(r=0.331, P=0.037),CRP(r=0.324, P=0.042) and DAS28 score(r=0.404, P=0.010), DAS28 score in GPI positive group was higher than GPI negative group after 3 months' treatment[(3.27±0.68) vs. (3.00±0.58)], and the difference was statistically significant(P<0.05). The difference was not statistically significant in Sharp score and bone mineral density between the two groups before and after treatment. Conclusions GPI can be used as an indicator of RA disease activity, which has nothing to do with bone erosion, but may play a role in evaluating prognosis.
Padyukov L. Genetics of rheumatoid arthritis[J].Semin Immunopathol, 2022, 44(1):47-62.
[2]
Almutairi K, Nossent J, Preen D, et al. The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review[J]. Rheumatol Int, 2021, 41(5):863-877.
[3]
Choudhary N, Bhatt L K, Prabhavalkar K S. Experimental animal models for rheumatoid arthritis[J]. Immunopharmacol Immunotoxicol, 2018, 40(3):193-200.
Peterfy C G, Wu C, Lu Y, et al. Comparison of the Genant-modified Sharp and van der Heijde-modified Sharp scoring methods for radiographic assessment in rheumatoid arthritis[J]. Int J Clin Rheumatol, 2011, 6(1): 15-24.
[7]
Batko B, Batko K, Krzanowski M, et al. Physician adherence to treat-to-target and practice guidelines in rheumatoid arthritis[J]. J Clin Med, 2019, 8(9): 1416.
[8]
Conforti A, di Cola I, Pavlych V, et al. Beyond the joints, the extra-articular manifestations in rheumatoid arthritis[J].Autoimmun Rev,2021,20(2):102735.
Zong M, Lu T B, Fan S S, et al. Glucose-6-phosphate isomerase promotes the proliferation and inhibits the apoptosis in fibroblast-like synoviocytes in rheumatoid arthritis[J]. Arthritis Res Ther, 2015, 17 (1): 100.
[14]
Ebbinghaus M, Müller S, Segond von Banchet G, et al. Contribution of inflammation and bone destruction to pain in arthritis: a study in murine glucose-6-phosphate isomerase-induced arthritis[J]. Arthritis Rheumatol, 2019, 71(12): 2016-2026.
Soleimani N, Hosseinzadeh M, Habibagahi Z. Value of serum glucose-6-phosphate isomerase in patients with rheumatoid arthritis and correlation with disease activity: a case-control study[J]. J Educ Health Promot, 2019, 8(1): 125.
[17]
Bruno D, Fedele A L, Tolusso B, et al. Systemic bone density at disease onset is associated with joint erosion progression in early naive to treatment rheumatoid arthritis: a prospective 12-month follow-up open-label study[J]. Front Med, 2021, 8(1): 613889.
[18]
Phuan-Udom R, Lektrakul N, Katchamart W. The association between 10-year fracture risk by FRAX and osteoporotic fractures with disease activity in patients with rheumatoid arthritis[J]. Clin Rheumatol, 2018, 37(10): 2603-2610.
[19]
Wysham K D, Shofer J, Lui G, et al. Low cumulative disease activity is associated with higher bone mineral density in a majority Latinx and Asian US rheumatoid arthritis cohort[J]. Semin Arthritis Rheum, 2022, 53(1):151972.
[20]
Jayakumar K, Norton S, Dixey J, et al. Sustained clinical remission in rheumatoid arthritis: prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS[J]. Rheumatology, 2012, 51(1): 169-175.
[21]
Xu J, Zhang X Y, Li R, et al. Glucose-6-phosphate isomerase is associated with disease activity and declines in response to infliximab treatment in rheumatoid arthritis[J]. Chin Med J (Engl), 2020, 133(8): 886-891.
2022, Vol. 33 
